203 related articles for article (PubMed ID: 28010983)
1. Intracavitary bacillus Calmette-Guérin for Superficial Bladder Tumors.
Droller MJ
J Urol; 2017 Feb; 197(2S):S146-S147. PubMed ID: 28010983
[No Abstract] [Full Text] [Related]
2. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
[TBL] [Abstract][Full Text] [Related]
4. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
7. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
Droller MJ
J Urol; 2001 Feb; 165(2):701-2. PubMed ID: 11233047
[No Abstract] [Full Text] [Related]
9. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy.
Ozbakkaloglu B; Tünger O; Sürücüoglu S; Lekili M; Kandiloglu AR
Int Urol Nephrol; 1999; 31(1):49-53. PubMed ID: 10408303
[TBL] [Abstract][Full Text] [Related]
10. The impact of the global bacille Calmette-Guérin shortage on treatment patterns: population-based data.
Perera M; Papa N; Christidis D; McGrath S; Manning T; Roberts M; Bolton D; Lawrentschuk N; Sengupta S
BJU Int; 2018 Feb; 121(2):169-172. PubMed ID: 29072817
[No Abstract] [Full Text] [Related]
11. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
12. Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer.
Danişman A; Bulut K; Kukul E; Ozen I; Sevük M
Urol Int; 2000; 64(4):198-201. PubMed ID: 10895085
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K
Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
[TBL] [Abstract][Full Text] [Related]
14. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
[TBL] [Abstract][Full Text] [Related]
15. [International Consensus Panel--treatment strategies for superficial bladder cancer].
Adler S; St Niclas M
Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
[No Abstract] [Full Text] [Related]
16. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
17. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
18. Case report: differential diagnosis of isolated iliac lymphadenopathy following Bacillus Calmette-Guérin treatment for high-risk superficial bladder cancer.
Biers SM; Di Marco A; Mostafid AH
Int Urol Nephrol; 2007; 39(4):1039-41. PubMed ID: 17431810
[TBL] [Abstract][Full Text] [Related]
19. Miliary tuberculosis of the lung in a patient treated with bacillus Calmette-Guerin for superficial bladder cancer.
Iantorno R; Nicolai M; Storto ML; Ciccotosto C; Cipollone G; Mastroprimiano G; Tenaglia RL
J Urol; 1998 May; 159(5):1639-40. PubMed ID: 9554372
[No Abstract] [Full Text] [Related]
20. Small bladder and multiple urethral recurrences after intravesical instillation of bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
Manasia P; Alcaraz A; Cetina A; Alcover J
J Urol; 2001 Feb; 165(2):529-30. PubMed ID: 11176420
[No Abstract] [Full Text] [Related]
[Next] [New Search]